## Aaron M Newman

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3285055/publications.pdf

Version: 2024-02-01

87 papers

29,676 citations

41 h-index 75 g-index

98 all docs 98 docs citations

98 times ranked 37842 citing authors

#	Article	IF	CITATIONS
1	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nature Medicine, 2022, 28, 353-362.	15.2	132
2	Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nature Communications, 2022, 13, 898.	5.8	19
3	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
4	Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	50
5	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1422-1437.e10.	7.7	102
6	Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell, 2021, 184, 5482-5496.e28.	13.5	116
7	Integrated spatial multiomics reveals fibroblast fate during tissue repair. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	76
8	Single Cell Analysis of Adult Human Hematopoietic Stem and Progenitor Cells Identifies a Novel Lymphoid Primed Multipotent Progenitor That Expands in Relapsed Acute Myeloid Leukemia. Blood, 2021, 138, 3259-3259.	0.6	0
9	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology, 2020, 158, 494-505.e6.	0.6	147
10	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
11	LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis. Cell Stem Cell, 2020, 27, 284-299.e8.	5.2	12
12	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research, 2020, 26, 6176-6186.	3.2	13
13	Single-cell transcriptional diversity is a hallmark of developmental potential. Science, 2020, 367, 405-411.	6.0	557
14	Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods in Molecular Biology, 2020, 2117, 135-157.	0.4	249
15	Abstract 3443: Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors. , 2020, , .		O
16	Abstract 5666: A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. , 2020, , .		0
17	Computational approaches for characterizing the tumor immune microenvironment. Immunology, 2019, 158, 70-84.	2.0	30
18	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	13.5	138

#	Article	IF	CITATIONS
19	Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology, 2019, 37, 773-782.	9.4	2,396
20	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	0.8	2
21	A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPα expression. Nature Communications, 2019, 10, 794.	5.8	46
22	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 2019, 10, 5712.	5.8	27
23	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	0.6	4
24	Abstract 1690: A tumor deconvolution DREAM Challenge: Inferring immune infiltration from bulk gene expression data. , 2019, , .		2
25	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clinical Cancer Research, 2018, 24, 2688-2699.	3.2	45
26	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
27	Genomic feature selection by coverage design optimization. Journal of Applied Statistics, 2018, 45, 2658-2676.	0.6	1
28	Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology, 2018, 1711, 243-259.	0.4	1,936
29	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
30	Method of Isolating and Transplanting the Hematopoietic Stem Cell with Its Microenvironment Which Improves Functional Hematopoietic Engraftment. Journal of the American College of Surgeons, 2018, 227, e224.	0.2	0
31	Complex mammalian-like haematopoietic system found in a colonial chordate. Nature, 2018, 564, 425-429.	13.7	60
32	Urochordata: Botryllus – Natural Chimerism and Tolerance Induction in a Colonial Chordate. , 2018, , 503-519.		0
33	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. Journal of Clinical Investigation, 2018, 128, 715-720.	3.9	298
34	(S012) Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. International Journal of Radiation Oncology Biology Physics, 2017, 98, E4.	0.4	0
35	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature, 2017, 543, 723-727.	13.7	232
36	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	7.7	701

#	Article	IF	CITATIONS
37	Role of <i>KEAP1</i> /i>NRF2 and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery, 2017, 7, 86-101.	7.7	239
38	Targeted chromatin ligation, a robust epigenetic profiling technique for small cell numbers. Nucleic Acids Research, 2017, 45, e153-e153.	6.5	16
39	Data normalization considerations for digital tumor dissection. Genome Biology, 2017, 18, 128.	3.8	25
40	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. JCI Insight, 2017, 2, .	2.3	15
41	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA) Journal of Clinical Oncology, 2017, 35, 3591-3591.	0.8	27
42	Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer Journal of Clinical Oncology, 2017, 35, 4055-4055.	0.8	3
43	Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies Journal of Clinical Oncology, 2017, 35, 8519-8519.	0.8	3
44	High-throughput genomic profiling of tumor-infiltrating leukocytes. Current Opinion in Immunology, 2016, 41, 77-84.	2.4	43
45	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA., 2016,,.		0
46	Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4464-4469.	3.3	70
47	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	5.8	348
48	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	5.8	520
49	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	9.4	837
50	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1089-1089.	0.6	8
51	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. Blood, 2016, 128, 1752-1752.	0.6	8
52	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics Journal of Clinical Oncology, 2016, 34, 7511-7511.	0.8	3
53	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib Journal of Clinical Oncology, 2016, 34, 9000-9000.	0.8	2
54	Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in <i>ALK+</i> non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, 9061-9061.	0.8	9

#	Article	IF	CITATIONS
55	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC Journal of Clinical Oncology, 2016, 34, e20500-e20500.	0.8	1
56	Noninvasive molecular subtyping and risk stratification of DLBCL Journal of Clinical Oncology, 2016, 34, 7554-7554.	0.8	2
57	Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens. Blood, 2016, 128, 915-915.	0.6	0
58	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2930-2930.	0.6	8
59	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood, 2016, 128, 4107-4107.	0.6	1
60	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	15.2	2,505
61	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 2015, 15, 715-719.	1.5	75
62	Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science, 2015, 348, aaa2151.	6.0	520
63	Robust enumeration of cell subsets from tissue expression profiles. Nature Methods, 2015, 12, 453-457.	9.0	8,460
64	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 114-114.	0.6	10
65	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 130-130.	0.6	9
66	Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLoS ONE, 2015, 10, e0133627.	1.1	90
67	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL) Journal of Clinical Oncology, 2015, 33, 8539-8539.	0.8	0
68	Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers. Cancer Research, 2015, 75, PR09-PR09.	0.4	3
69	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 2014, 20, 548-554.	15.2	1,771
70	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics, 2014, 30, 3390-3393.	1.8	212
71	Efficient Selection of Biomineralizing DNA Aptamers Using Deep Sequencing and Population Clustering. ACS Nano, 2014, 8, 387-395.	7.3	33
72	InÂVivo Clonal Analysis Reveals Lineage-Restricted Progenitor Characteristics in Mammalian Kidney Development, Maintenance, and Regeneration. Cell Reports, 2014, 7, 1270-1283.	2.9	199

#	Article	IF	Citations
73	Identifying Stem Cell Gene Expression Patterns and Phenotypic Networks with AutoSOME. Methods in Molecular Biology, 2014, 1150, 115-130.	0.4	1
74	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing Journal of Clinical Oncology, 2014, 32, 11016-11016.	0.8	0
75	Identification of a Colonial Chordate Histocompatibility Gene. Science, 2013, 341, 384-387.	6.0	91
76	The genome sequence of the colonial chordate, Botryllus schlosseri. ELife, 2013, 2, e00569.	2.8	209
77	Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Medicine, 2012, 4, 16.	3.6	234
78	Exploring Stem Cell Gene Expression Signatures using AutoSOME Cluster Analysis., 2012,, 44-70.		1
79	Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study. Blood, 2012, 120, 1231-1231.	0.6	0
80	Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival Blood, 2012, 120, 2390-2390.	0.6	3
81	The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. Blood, 2012, 120, 790-790.	0.6	1
82	Global Analysis of Proline-Rich Tandem Repeat Proteins Reveals Broad Phylogenetic Diversity in Plant Secretomes. PLoS ONE, 2011, 6, e23167.	1.1	16
83	A proteomic approach for the identification of novel lysine methyltransferase substrates. Epigenetics and Chromatin, $2011, 4, 19$ .	1.8	55
84	clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics, 2011, 12, 436.	1.2	541
85	AutoSOME: a clustering method for identifying gene expression modules without prior knowledge of cluster number. BMC Bioinformatics, 2010, 11, 117.	1.2	92
86	Lab-Specific Gene Expression Signatures in Pluripotent Stem Cells. Cell Stem Cell, 2010, 7, 258-262.	5.2	195
87	XSTREAM: A practical algorithm for identification and architecture modeling of tandem repeats in protein sequences. BMC Bioinformatics, 2007, 8, 382.	1.2	145